Your browser is no longer supported. Please, upgrade your browser.
Repligen Corporation
Index- P/E145.68 EPS (ttm)1.44 Insider Own0.80% Shs Outstand54.80M Perf Week4.89%
Market Cap11.31B Forward P/E82.97 EPS next Y2.53 Insider Trans-16.09% Shs Float51.06M Perf Month8.81%
Income79.60M PEG4.62 EPS next Q0.52 Inst Own84.60% Short Float3.33% Perf Quarter-3.85%
Sales433.00M P/S26.12 EPS this Y155.50% Inst Trans0.05% Short Ratio4.28 Perf Half Y-4.29%
Book/sh28.40 P/B7.39 EPS next Y12.15% ROA4.70% Target Price238.86 Perf Year53.53%
Cash/sh13.20 P/C15.90 EPS next 5Y31.50% ROE6.00% 52W Range131.91 - 228.84 Perf YTD9.54%
Dividend- P/FCF309.88 EPS past 5Y31.90% ROI4.00% 52W High-8.27% Beta0.86
Dividend %- Quick Ratio2.60 Sales past 5Y34.40% Gross Margin57.40% 52W Low59.14% ATR6.00
Employees1128 Current Ratio3.00 Sales Q/Q87.60% Oper. Margin21.80% RSI (14)64.46 Volatility3.00% 2.77%
OptionableYes Debt/Eq0.16 EPS Q/Q180.20% Profit Margin18.40% Rel Volume1.34 Prev Close206.01
ShortableYes LT Debt/Eq0.00 EarningsJul 27 BMO Payout0.00% Avg Volume396.81K Price209.92
Recom1.70 SMA204.37% SMA5010.40% SMA2007.80% Volume530,972 Change1.90%
Nov-10-20Initiated KeyBanc Capital Markets Overweight $241
Aug-24-20Reiterated H.C. Wainwright Buy $151 → $168
Jun-30-20Reiterated H.C. Wainwright Buy $143 → $151
May-07-20Reiterated H.C. Wainwright Buy $100 → $143
Mar-23-20Reiterated H.C. Wainwright Buy $110 → $100
Nov-15-19Initiated Stifel Buy
Nov-01-19Upgrade First Analysis Sec Outperform → Strong Buy $107 → $110
Oct-15-19Initiated SVB Leerink Outperform $100
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Feb-13-17Upgrade Piper Jaffray Neutral → Overweight
Jul-22-21 06:15AM  
Jul-20-21 03:02PM  
Jul-19-21 11:32AM  
Jul-16-21 01:54PM  
Jul-15-21 01:43PM  
Jul-13-21 10:21AM  
Jul-09-21 05:45AM  
Jul-08-21 11:23AM  
Jul-06-21 08:50AM  
Jul-05-21 05:28AM  
Jul-02-21 11:01AM  
Jul-01-21 10:32AM  
Jun-30-21 11:08AM  
Jun-29-21 11:15AM  
Jun-28-21 11:18AM  
Jun-24-21 12:38PM  
Jun-22-21 07:20AM  
Jun-21-21 05:05PM  
Jun-18-21 11:08AM  
Jun-16-21 11:49AM  
Jun-11-21 12:38PM  
Jun-10-21 12:12PM  
Jun-09-21 10:28AM  
Jun-08-21 06:08AM  
Jun-03-21 11:31AM  
Jun-02-21 11:02AM  
May-31-21 05:16PM  
May-27-21 03:08PM  
May-25-21 07:30AM  
May-24-21 03:36PM  
May-21-21 08:46AM  
May-20-21 10:14AM  
May-19-21 10:38AM  
May-18-21 05:27PM  
May-17-21 06:29AM  
May-14-21 02:04PM  
May-12-21 03:32PM  
May-11-21 11:30AM  
May-10-21 07:35AM  
May-09-21 04:33AM  
May-07-21 12:17PM  
May-04-21 04:18PM  
Apr-30-21 10:28AM  
Apr-28-21 02:57PM  
Apr-27-21 10:51AM  
Apr-20-21 09:46AM  
Apr-13-21 05:27PM  
Apr-12-21 10:53AM  
Apr-09-21 10:57AM  
Apr-07-21 05:14PM  
Apr-06-21 12:33PM  
Apr-05-21 01:16PM  
Apr-01-21 08:17AM  
Mar-30-21 11:43AM  
Mar-28-21 06:11AM  
Mar-26-21 11:30AM  
Mar-25-21 08:56AM  
Mar-19-21 09:17AM  
Mar-17-21 07:30AM  
Mar-09-21 09:31AM  
Mar-08-21 10:56AM  
Mar-03-21 12:40PM  
Mar-02-21 10:02AM  
Mar-01-21 10:33AM  
Feb-25-21 11:56PM  
Feb-24-21 04:41PM  
Feb-22-21 07:30AM  
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAWES KAREN ADirectorJul 20Sale202.094,585926,605112,877Jul 22 08:25 PM
DAWES KAREN ADirectorJul 13Option Exercise41.192,929120,646118,982Jul 15 05:17 PM
KURIYEL RALFSenior VP, R&DJun 10Option Exercise67.233,602242,16728,157Jun 14 06:48 PM
KURIYEL RALFSenior VP, R&DJun 10Sale189.196,8021,286,87021,355Jun 14 06:48 PM
Hunt AnthonyChief Executive OfficerMay 19Sale171.4122,2673,816,698190,495May 20 09:00 PM
Gebski ChristineSee RemarksMay 14Sale172.2544576,65136,695May 18 07:52 AM
KURIYEL RALFSenior VP, R&DMay 14Sale172.29710122,32624,555May 18 07:50 AM
Snodgres JonChief Financial OfficerMay 14Sale172.6047081,12231,893May 18 07:49 AM
DAWES KAREN ADirectorMay 11Option Exercise3.2215,00048,300115,734May 13 05:01 PM
DAWES KAREN ADirectorMay 11Sale176.8528550,402115,449May 13 05:01 PM
Bylund JamesSVP, Global Operations & ITApr 06Sale204.2536073,5306,324Apr 08 07:55 PM
Gebski ChristineSee RemarksMar 16Sale196.881,400275,63237,140Mar 18 09:47 PM
Hunt AnthonyChief Executive OfficerMar 12Sale190.389,1021,732,847212,762Mar 12 07:34 PM
KURIYEL RALFSenior VP, R&DMar 10Option Exercise34.158,000273,16833,265Mar 12 07:33 PM
KURIYEL RALFSenior VP, R&DMar 10Sale190.448,0001,523,50125,265Mar 12 07:33 PM
Hunt AnthonyChief Executive OfficerMar 04Sale190.1921,9004,165,091221,864Mar 08 09:51 PM
Snodgres JonChief Financial OfficerMar 04Sale192.473,545682,29532,363Mar 08 09:50 PM
KURIYEL RALFSenior VP, R&DMar 04Sale192.002,075398,39625,265Mar 08 09:41 PM
RYAN THOMAS F JRDirectorMar 03Option Exercise26.121,00026,1202,464Mar 04 09:22 PM
RYAN THOMAS F JRDirectorMar 03Sale205.001,000205,0001,464Mar 04 09:22 PM
Snodgres JonChief Financial OfficerJan 25Option Exercise33.874,000135,48033,498Jan 26 09:59 PM
Snodgres JonChief Financial OfficerJan 04Sale191.523,957757,84029,498Jan 06 04:41 PM
KURIYEL RALFSenior VP, R&DDec 16Sale186.1843580,98825,654Dec 18 04:30 PM
Hunt AnthonyChief Executive OfficerNov 19Option Exercise26.0520,000521,000253,327Nov 23 07:03 PM
Hunt AnthonyChief Executive OfficerNov 19Sale185.8020,0003,716,051233,327Nov 23 07:03 PM
RYAN THOMAS F JRDirectorNov 11Option Exercise38.7693436,2022,398Nov 13 04:46 PM
RYAN THOMAS F JRDirectorNov 11Sale187.73934175,3401,464Nov 13 04:46 PM
Snodgres JonChief Financial OfficerNov 10Option Exercise32.403,08699,98636,541Nov 10 09:17 PM
Snodgres JonChief Financial OfficerNov 10Sale193.003,086595,59833,455Nov 10 09:17 PM
Snodgres JonChief Financial OfficerNov 09Option Exercise59.521,893112,67133,455Nov 10 09:17 PM
BARTHELEMY NICOLASDirectorNov 09Sale195.511,214237,3491,450Nov 10 09:18 PM
Snodgres JonChief Financial OfficerNov 09Sale194.69705137,25631,562Nov 10 09:17 PM
Hunt AnthonyChief Executive OfficerSep 10Option Exercise26.0545,3511,181,394278,678Sep 14 07:43 AM
Hunt AnthonyChief Executive OfficerSep 10Sale148.2045,3516,721,018233,327Sep 14 07:43 AM
KURIYEL RALFSenior VP, R&DAug 06Option Exercise33.875,000169,35031,089Aug 10 05:35 PM
KURIYEL RALFSenior VP, R&DAug 06Sale153.795,000768,95026,089Aug 10 05:35 PM
RYAN THOMAS F JRDirectorJul 31Option Exercise67.712,109142,8004,559Aug 04 07:50 PM
RYAN THOMAS F JRDirectorJul 31Sale151.903,095470,1291,464Aug 04 07:50 PM